Tag:

Leo Pharma

Latest Headlines

Latest Headlines

LEO snags option on oral anti-inflammatory in potential $125M 4SC deal

Denmark's LEO Pharma has anted up $1.25 million and some research cash to take an option on an anti-inflammatory program from Germany's 4SC. And if LEO decides to snare the potential treatment for skin diseases like psoriasis, the biotech will pay an additional $4 million followed by milestones that reach up to $120 million.

LEO Pharma slapped with sales-rep overtime suit

The sales-rep overtime fight is spreading. Four LEO Pharma salespeople have filed a putative class action, alleging they're owed overtime under U.S. wage-and-hour laws. The reps accuse LEO of...

Novo leads revolt against Greek price cuts

Novo Nordisk (NYSE: NVO) doesn't like the Greek price cuts. So, instead of discounting its medicines by 25 percent as ordered, it's keeping prices the same on its newest insulin products, forcing

Warner Chilcott returns rights to Leo Pharma for $1B

Leo Pharma will reacquire the licensing rights to its topical psoriasis treatments from Warner Chilcott for about $1 billion, the two drugmakers announced today. The deal, which is expected to be

LEO snags Peplin, lesion therapy in $287M buyout

Looking to boost its pipeline for dermatology products, Denmark's LEO Pharma has agreed to buy out Peplin for $287.5 million. The acquisition values Peplin at $16.99 a share and LEO will also extend